Αρχειοθήκη ιστολογίου

Κυριακή 10 Σεπτεμβρίου 2017

ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advcanced renal carcinoma

Interim results were announced today from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib, a multiple receptor tyrosine kinase inhibitor (including fibroblast growth factor receptors), in...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wTfYUf
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader